Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
NIH – National Institute On Aging
NIH – National Institute On Aging
Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
Gait abnormalities in older adults with transthyretin cardiac amyloidosis
Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics
Limited English Proficiency in Older Adults Referred to the Cardiovascular Team
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption
Analysis of lumbar spine stenosis specimens for identification of amyloid
N-of-1 trials to facilitate evidence-based deprescribing: Rationale and case study
Systemic embolism in amyloid transthyretin cardiomyopathy
Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis
Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week
Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
Cardiovascular Diseases That Have Emerged From the Darkness
Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis: Caveat Emptor
Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis